Herpes Zoster Vaccines

被引：115
作者：
Harbecke, Ruth [1 ,2 ]
Cohen, Jeffrey, I [3 ]
Oxman, Michael N. [1 ,2 ,4 ]
机构：
[1] Dept Vet Affairs VA San Diego Healthcare Syst, San Diego, CA USA
[2] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
[3] NIAID, Lab Infect Dis, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA
[4] Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA
来源：
JOURNAL OF INFECTIOUS DISEASES | 2021年 / 224卷
关键词：
herpes zoster; zoster vaccine; live attenuated Oka varicella-zoster vaccine; recombinant zoster vaccine; SUBUNIT VACCINE; SAFETY; EFFICACY; ADULTS;
D O I：
10.1093/infdis/jiab387
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Herpes zoster (HZ) affects approximately 1 in 3 persons in their lifetime, and the risk of HZ increases with increasing age. The most common, debilitating complication of HZ is the chronic neuropathic pain of postherpetic neuralgia (PHN). Two herpes zoster vaccines, a live-attenuated varicella-zoster virus (VZV) vaccine (zoster vaccine live [ZVL]; ZOSTAVAX [Merck]) and an adjuvanted VZV glycoprotein E (gE) subunit vaccine (recombinant zoster vaccine [RZV]; SHINGRIX [GlaxoSmithKline]) are licensed for the prevention of HZ and PHN in healthy older adults. The safety and efficacy of both vaccines has been demonstrated in clinical trials in immunocompetent adults and in selected immunocompromised persons and persons with immune-mediated diseases. Numerous real-world effectiveness studies have confirmed the safety and effectiveness of both ZVL and RZV. Recombinant zoster vaccine (RZV) is more effective for prevention of HZ than ZVL. Recombinant zoster vaccine is nonreplicating and is thus safe in immunocompromised persons. Additional zoster vaccines are in different stages of development. Wider distribution of safe and effective zoster vaccines will improve the health and well being of the rapidly growing population of older adults around the world.
引用
收藏
页码：S429 / S442
页数：14
相关论文
共 15 条
[1]   Safety and Immunogenicity of Zoster Vaccine Live in Human Immunodeficiency Virus-Infected Adults With CD4+ Cell Counts >200 Cells/mL Virologically Suppressed on Antiretroviral Therapy [J].
Benson, Constance A. ;
Andersen, Janet W. ;
Macatangay, Bernard J. C. ;
Mailliard, Robbie B. ;
Rinaldo, Charles R., Jr. ;
Read, Sarah ;
Bozzolo, Dawn R. ;
Purdue, Lynette ;
Jennings, Cheryl ;
Keefer, Michael C. ;
Glesby, Marshall ;
Tebas, Pablo ;
Russell, Amy Falk ;
Martin, Jason ;
Annunziato, Paula ;
Popmihajlov, Loran ;
Lennox, Jeffrey L. .
CLINICAL INFECTIOUS DISEASES, 2018, 67 (11) :1712-1719
[2]   Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo-Controlled Study [J].
Berkowitz, Elchonon M. ;
Moyle, Graeme ;
Stellbrink, Hans-Juergen ;
Schuermann, Dirk ;
Kegg, Stephen ;
Stoll, Matthias ;
El Idrissi, Mohamed ;
Oostvogels, Lidia ;
Heineman, Thomas C. .
JOURNAL OF INFECTIOUS DISEASES, 2015, 211 (08) :1279-1287
[3]   Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory [J].
Coplan, PM ;
Schmader, K ;
Nikas, A ;
Chan, ISF ;
Choo, P ;
Levin, MJ ;
Johnson, G ;
Bauer, M ;
Williams, HM ;
Kaplan, KM ;
Guess, HA ;
Oxman, MN .
JOURNAL OF PAIN, 2004, 5 (06) :344-356
[4]   Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older [J].
Cunningham, A. L. ;
Lal, H. ;
Kovac, M. ;
Chlibek, R. ;
Hwang, S. -J. ;
Diez-Domingo, J. ;
Godeaux, O. ;
Levin, M. J. ;
McElhaney, J. E. ;
Puig-Barbera, J. ;
Abeele, C. Vanden ;
Vesikari, T. ;
Watanabe, D. ;
Zahaf, T. ;
Ahonen, A. ;
Athan, E. ;
Barba-Gomez, J. F. ;
Campora, L. ;
de Looze, F. ;
Downey, H. J. ;
Ghesquiere, W. ;
Gorfinkel, I. ;
Korhonen, T. ;
Leung, E. ;
McNeil, S. A. ;
Oostvogels, L. ;
Rombo, L. ;
Smetana, J. ;
Weckx, L. ;
Yeo, W. ;
Heineman, T. C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (11) :1019-1032
[5]   Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis [J].
Dagnew, Alemnew F. ;
Ilhan, Osman ;
Lee, Won-Sik ;
Woszczyk, Dariusz ;
Kwak, Jae-Yong ;
Bowcock, Stella ;
Sohn, Sang Kyun ;
Rodriguez Macias, Gabriela ;
Chiou, Tzeon-Jye ;
Quiel, Dimas ;
Aoun, Mickael ;
Navarro Matilla, Maria Belen ;
de la Serna, Javier ;
Milliken, Samuel ;
Murphy, John ;
McNeil, Shelly A. ;
Salaun, Bruno ;
Di Paolo, Emmanuel ;
Campora, Laura ;
Lopez-Fauqued, Marta ;
El Idrissi, Mohamed ;
Schuind, Anne ;
Heineman, Thomas C. ;
Van den Steen, Peter ;
Oostvogels, Lidia .
LANCET INFECTIOUS DISEASES, 2019, 19 (09) :988-1000
[6]   Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines [J].
Dooling, Kathleen L. ;
Guo, Angela ;
Patel, Manisha ;
Lee, Grace M. ;
Moore, Kelly ;
Belongia, Edward A. ;
Harpaz, Rafael .
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2018, 67 (03) :103-108
[7]   The Epidemiology of Herpes Zoster in the United States During the Era of Varicella and Herpes Zoster Vaccines: Changing Patterns Among Older Adults [J].
Harpaz, Rafael ;
Leung, Jessica W. .
CLINICAL INFECTIOUS DISEASES, 2019, 69 (02) :341-344
[8]  
Hesse EM, 2019, MMWR-MORBID MORTAL W, V68, P91, DOI 10.15585/mmwr.mm6804a4
[9]   NATURE OF HERPES ZOSTER - A LONG-TERM STUDY AND A NEW HYPOTHESIS [J].
HOPESIMPSON, RE .
PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON, 1965, 58 (01) :9-+
[10]   Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults [J].
Lal, Himal ;
Cunningham, Anthony L. ;
Godeaux, Olivier ;
Chlibek, Roman ;
Diez-Domingo, Javier ;
Hwang, Shinn-Jang ;
Levin, Myron J. ;
McElhaney, Janet E. ;
Poder, Airi ;
Puig-Barbera, Joan ;
Vesikari, Timo ;
Watanabe, Daisuke ;
Weckx, Lily ;
Zahaf, Toufik ;
Heineman, Thomas C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (22) :2087-2096
12